To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., et al. (2016). Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. JOURNAL OF CLINICAL ONCOLOGY, 34(9), 972-979 [10.1200/JCO.2015.64.0060].
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
AMADORI, SERGIO;VENDITTI, ADRIANO;VOSO, MARIA TERESA;MAZZONE, CARLA;DE FABRITIIS, PAOLO;MANCINI, MARCO;
2016-03-20
Abstract
To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
